Effects of Rosuvastatin Combined With Olmesartan, Irbesartan, or Telmisartan on Indices of Glucose Metabolism in Greek Adults With Impaired Fasting Glucose, Hypertension, and Mixed Hyperlipidemia: A 24-Week, Randomized, Open-Label, Prospective Study

摘要

Background: Statin therapy has been reported to be associated with new-onset diabetes. Angiotensin II-receptor blockers (ARBs) are effective antihypertensive drugs that have been reported to activate peroxisome proliferator-activated receptor y (PPARy) to differing extents, with favorable effects on glucose metabolism and the incidence of new-onset diabetes. Among the ARBs, telmisartan is a partial activator of PPARgamma, irbesartan is a weak partial activator, and olmesartan has no effect on PPARy activation.Objective: The goal of this study was to evaluate the effects on glucose homeostasis of combining rosuvastatin with ARBs of varying PPARy-activating potency in Greek adults with impaired fasting glucose, mixed dyslipidemia, and stage 1 hypertension.